Evidence map›Paper›PMID 29789365›Full record

Trial reportmBio2018

Structural Alteration of Gut Microbiota during the Amelioration of Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial.

Xiaolin Tong, Jia Xu, Fengmei Lian, Xiaotong Yu, Yufeng Zhao, Lipeng Xu, Menghui Zhang, Xiyan Zhao, Jian Shen, Shengping Wu and 14 more

Open access · goldFull text readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in mBio, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 225 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
225citing papers in PubMed, 14 pooled it
13.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

225 citing papers in PubMed, 14 syntheses or guidelines pooled it, 381 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

165 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 4 institutions in 1 country.

Xiaolin Tong *Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China xiaolintong66@sina.com lpzhao@sjtu.edu.cn.
Jia Xu *State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Fengmei Lian *Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Xiaotong YuGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Yufeng ZhaoShanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Lipeng XuGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Menghui ZhangState Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Xiyan ZhaoGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Jian ShenShanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Shengping WuGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Xiaoyan PangState Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Jiaxing TianGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Chenhong ZhangState Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Qiang ZhouGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Linhua WangState Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Bing PangGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Feng ChenState Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Zhiping PengGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Jing WangState Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Zhong ZhenGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Chao FangState Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Min LiGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Limei ChenState Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Liping ZhaoState Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, People's Republic of China xiaolintong66@sina.com lpzhao@sjtu.edu.cn.
Shanghai Jiao Tong University · CNGuang’anmen Hospital · CNBeijing University of Chinese Medicine · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating evidence implicates gut microbiota as promising targets for the treatment of type 2 diabetes mellitus (T2DM). With a randomized clinical trial, we tested the hypothesis that alteration of gut microbiota may be involved in the alleviation of T2DM with hyperlipidemia by metformin and a specifically designed herbal formula (AMC). Four hundred fifty patients with T2DM and hyperlipidemia were randomly assigned to either the metformin- or AMC-treated group. After 12 weeks of treatment, 100 patients were randomly selected from each group and assessed for clinical improvement. The effects of the two drugs on the intestinal microbiota were evaluated by analyzing the V3 and V4 regions of the 16S rRNA gene by Illumina sequencing and multivariate statistical methods. Both metformin and AMC significantly alleviated hyperglycemia and hyperlipidemia and shifted gut microbiota structure in diabetic patients. They significantly increased a coabundant group represented by

Indexed as

AdolescentAdultAgedAnti-Obesity AgentsBacteriaBlood GlucoseDiabetes Mellitus, Type 2Drugs, Chinese HerbalFemaleGastrointestinal MicrobiomeHumansHyperlipidemiasMaleMetforminMiddle AgedTriglyceridesAnti-Obesity AgentsBlood GlucoseDrugs, Chinese HerbalMetforminTriglyceridesclinical trialgut microbiotahyperlipidemiametformintraditional Chinese medicinetype 2 diabetes

Identifiers

PMID29789365
PMCPMC5964358
OpenAlexW2803132482

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.